Pancreatic Cancer Research

ResearcherInsermActive in the last 2 years

Benedetta Ferrara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2569-5115; OpenAlex author ID A5047889667. Sources: OpenAlex.

Their work

Papers
9
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 9

  1. An oncogenic KRAS-driven secretome involving TNFα promotes niche preparation prior to pancreatic cancer onset. Co-author DOI 10.1186/s12943-025-02541-1↗
  2. The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1016/j.ejphar.2025.177310↗
  3. Corrigendum to "The nucleolin antagonist N6L and paclitaxel combination treatment could be a new promising therapeutic strategy for pancreatic ductal adenocarc… Co-author DOI 10.1016/j.ejphar.2025.177383↗
  4. Matrix stiffness regulates the protein profile of extracellular vesicles of pancreatic cancer cell lines. Co-author DOI 10.1002/pmic.202400058↗
  5. Establishment of a Transplantation Model of PDAC-Derived Liver Metastases. Co-author DOI 10.1245/s10434-024-15514-3↗
  6. ASO Author Reflections: Bridging the Gap in PDAC Research: The Intraportal Model as a Platform for Studying Preclinical Liver Metastasis. Co-author DOI 10.1245/s10434-024-15655-5↗
  7. A Comprehensive Characterization of Stemness in Cell Lines and Primary Cells of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/ijms231810663↗
  8. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Co-author DOI 10.3390/cancers13174442↗
  9. Fabrication of large pore mesoporous silica microspheres by salt-assisted spray-drying method for enhanced antibacterial activity and pancreatic cancer treatme… Co-author DOI 10.1016/j.ijpharm.2020.119930↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lorenzo Piemonti · 5 shared papers, 2021–2026 · strength 0.92
  2. Ilaria Cascone · 4 shared papers, 2020–2025 · strength 0.78
  3. José Laurent Cohen · 3 shared papers, 2024–2025 · strength 0.66
  4. Paolo Riccardo Camisa · 3 shared papers, 2024–2026 · strength 0.60
  5. Sabrina Belbekhouche · 3 shared papers, 2020–2025 · strength 0.59
  6. Erica Dugnani · 3 shared papers, 2022–2024 · strength 0.57
  7. Fabrice Raineri · 2 shared papers, 2025 · strength 0.47
  8. Claudio Doglioni · 2 shared papers, 2024 · strength 0.40
  9. Marco Schiavo Lena · 2 shared papers, 2024 · strength 0.40
  10. Chantal Allgöwer · 1 shared paper, 2026 · strength 0.19
  11. Élodie Roger · 1 shared paper, 2026 · strength 0.19
  12. Claus Jørgensen · 1 shared paper, 2026 · strength 0.19
  13. Michael Karl Melzer · 1 shared paper, 2026 · strength 0.19
  14. Dharini Srinivasan · 1 shared paper, 2026 · strength 0.19
  15. Anton Lahusen · 1 shared paper, 2026 · strength 0.19
  16. Alexander Kleger · 1 shared paper, 2026 · strength 0.19
  17. Thomas Theodor Werner Seufferlein · 1 shared paper, 2026 · strength 0.19
  18. Stefano Crippa · 1 shared paper, 2026 · strength 0.19
  19. Valentina Pasquale · 1 shared paper, 2022 · strength 0.16
  20. Gianpaolo Balzano · 1 shared paper, 2022 · strength 0.16
  21. Michele Reni · 1 shared paper, 2022 · strength 0.16
  22. Alfred P. Weber · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.